HOPE-3 Trial Success: Recent discussions on X about Capricor Therapeutics (CAPR) have exploded following the announcement of positive topline results from the Phase 3 HOPE-3 study. The study showed that their cell therapy, Deramiocel, slowed Duchenne muscular dystrophy progression by 54% in skeletal function and 91% in cardiac function. Posts on X highlight the stock’s massive surge, with some noting gains of over 400% in a single day.
Market Momentum: Many on X are buzzing about the potential for further upside, pointing to analyst targets and renewed investor confidence. There’s talk of high short interest possibly fueling a multi-day rally as bears cover positions. The sentiment is overwhelmingly positive as users discuss the therapy’s impact on a devastating disease.
Safety and Outlook: Conversations also touch on the favorable safety profile of Deramiocel, consistent with prior data, as noted in recent posts. Some users speculate on the path to FDA approval, seeing this as a pivotal moment for the biotech. The excitement is palpable, with many eyeing the stock’s trajectory in the coming weeks.
Note: This discussion summary was generated from an AI condensation of post data.
Capricor Therapeutics Hedge Fund Activity
We have seen 58 institutional investors add shares of Capricor Therapeutics stock to their portfolio, and 88 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP removed 665,341 shares (-45.4%) from their portfolio in Q3 2025, for an estimated $4,797,108
- J. GOLDMAN & CO LP added 481,981 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,475,083
- DG CAPITAL MANAGEMENT, LLC added 470,333 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,391,100
- OCTAGON CAPITAL ADVISORS LP removed 450,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,468,500
- UBS GROUP AG removed 424,710 shares (-77.3%) from their portfolio in Q3 2025, for an estimated $3,062,159
- IKARIAN CAPITAL, LLC added 264,642 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,908,068
- SUPERSTRING CAPITAL MANAGEMENT LP removed 241,192 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,395,036
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Capricor Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $CAPR in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/25/2025
- B. Riley Securities issued a "Buy" rating on 06/26/2025
- Jones Trading issued a "Buy" rating on 06/25/2025
- Oppenheimer issued a "Outperform" rating on 06/23/2025
- Roth Capital issued a "Buy" rating on 06/17/2025
To track analyst ratings and price targets for Capricor Therapeutics, check out Quiver Quantitative's $CAPR forecast page.
Capricor Therapeutics Price Targets
Multiple analysts have issued price targets for $CAPR recently. We have seen 5 analysts offer price targets for $CAPR in the last 6 months, with a median target of $22.0.
Here are some recent targets:
- Boobalan Pachaiyappan from Roth Capital set a target price of $13.0 on 11/12/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $24.0 on 09/25/2025
- Madison El-Saadi from B. Riley Securities set a target price of $21.0 on 06/26/2025
- Catherine Novack from Jones Trading set a target price of $29.0 on 06/25/2025
- Leland Gershell from Oppenheimer set a target price of $22.0 on 06/23/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
